Munjaro joins heart protection race
The U.S. Food and Drug Administration (FDA) has issued a new approval for the drug Mounjaro, used to treat type 2 diabetes, to include reducing the risk of death associated with heart disease, heart attacks, and strokes in patients who are at high risk for these complications. This approval was based on the results of the SURPASS-CVOT study, which showed a relative reduction in the risk of death and cardiovascular disease by approximately 8% among Mounjaro users compared to the drug Trulicity, although the results did not definitively demonstrate statistical superiority. The medication is typically used to regulate blood sugar levels and suppress appetite and is considered only for adults with type 2 diabetes who have high cardiovascular risk factors. Each patient's health condition should be carefully evaluated before use.
Notice: This Is an AI-Generated Summary
Comments (0)